Premature Ovarian Failure
Conditions
Keywords
POF, ESS, stem cell
Brief summary
Out of 112 high risk patients for Premature Ovarian Failure (POF), diagnosis was established in 10 cases. ESS cut off point for menstruation and pregnancy was 6.
Detailed description
Out of 112 high risk patients for POF, diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by immubohistchemical (IH) staining by stem cell marker OCT4. IH expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Score (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS). These cases were of ESS 5 and 6.
Interventions
BIOLOGICALStem Cell
Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
Sponsors
Al-Azhar University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Post-menarche female less than 40 years old. * Normal karyotyping female. * Primary ovarian failure females * Follicle-stimulating hormone (FSH) more than or equal to 20 IU/L. * Agree to sign the designed consent for the study.
Exclusion criteria
* Autoimmune diseases. * Breast cancer, ovarian cancer. * Hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs. * Those with major medical problems such as malignancy, hepatitis, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pregnancy | 104 weeks | Hormonal analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Menstruation | 104 weeks | Clinical |
Other
| Measure | Time frame | Description |
|---|---|---|
| Ovulation | 104 weeks | Ultrasound |
Countries
Egypt
Outcome results
None listed